Lu Hongbo's Form 4 filing
Arrowhead Pharmaceuticals, Inc.ARWR · filed Mar 20, 2024
- Accession no.
- 0001628280-24-012327
- Filed
- Mar 20, 2024
- Trade date
- Mar 18-20, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $83.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lu HongboCIK 0001767584 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2024 | Common Stock | PPurchaseAcquired | +1,000 | $27.49F1 | +$27,490 | 31,680 | Direct | |
| Mar 19, 2024 | Common Stock | PPurchaseAcquired | +1,000 | $28.00 | +$28,000 | 32,680 | Direct | |
| Mar 20, 2024 | Common Stock | PPurchaseAcquired | +1,000 | $27.50 | +$27,500 | 33,680 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported on Column 4 is the weighted average price. These shares were purchase in multiple transactions at prices ranging from $ 27.48 to $ 27.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.